Discussion
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Lundbeck’s asedebart, a designation that may provide incentives for the development of this experimental antibody for endogenous Cushing’s syndrome. A Phase 2 trial is currently underway in people with Cushing’s disease, one form of the…